Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1671 1672
This examiner grants 31% of resolved cases
Immaculada Barrera is an examiner in Tech Center 1600 and Art Unit 1671. She has 29 resolved cases. Her allowance rate is 31.0 percent. The median days to allowance for her cases is 1306. This 1306-day figure provides a timeline for applicants to expect when their cases are granted.
The interview lift for this examiner is 80.0 percent. This 80.0 percent lift is an increase when compared to the 31.0 percent baseline. It suggests that cases involving an interview have a higher probability of allowance than those that do not. For practitioners in Art Unit 1671, this data point indicates that direct communication is an effective strategy.
With 29 resolved cases, the data for this examiner is established. The allowance rate and median pendency describe the typical outcome and timing for her docket. The interview lift is a significant metric, showing a statistical benefit to conducting an interview during the prosecution process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18080639 | VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES | Final Rejection | Janssen Biotech, Inc. |
| 18017955 | ADENOVIRUS VECTORS AND METHODS FOR USING ADENOVIRUS VECTORS | Final Rejection | Mayo Foundation for Medical Education and Research |
| 18561266 | PROTEIN ANTIGEN-BINDING MOLECULES | Non-Final OA | National University of Singapore |
| 18262522 | PNMA2-BASED CAPSIDS AND USES THEREOF | Final Rejection | University Of Utah Research Foundation |
| 18042955 | HUMAN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AGAINST CORONAVIRUS SPIKE PROTEIN | Non-Final OA | The University of Tokyo |
| 18021262 | Pharmaceutical Composition Comprising Hepatitis B Virus-Derived Polypeptide for Prevention or Treatment of Cancer | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18555940 | A VACCINE ADJUVANT FOR INFECTIOUS DISEASES | Non-Final OA | University of Cincinnati |
| 18255748 | A PROCESS AND A KIT FOR DETECTION OF CORONAVIRUS AND OTHER RESPIRATORY VIRUSES | Final Rejection | Council of Scientific and Industrial Research |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy